MedPath

Clinical Trials
Related News

A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

Phase 2
Not yet recruiting
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: Placebo
First Posted Date
2024-08-09
Last Posted Date
2024-08-14
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
884
Registration Number
NCT06547333

Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

Phase 1
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2023-12-08
Last Posted Date
2024-10-15
Lead Sponsor
Keymed Biosciences Co.Ltd
Target Recruit Count
24
Registration Number
NCT06162507
Locations
🇨🇳

Beijing Children's Hospital Capital Medical University, Beijing, China

Study of CM310 in Subjects With Allergic Rhinitis

Phase 3
Completed
Conditions
Allergic Rhinitis
Interventions
Biological: Placebo
First Posted Date
2023-06-18
Last Posted Date
2024-11-08
Lead Sponsor
Keymed Biosciences Co.Ltd
Target Recruit Count
108
Registration Number
NCT05908032
Locations
🇨🇳

Beijing Tong-Ren hospital, Beijing, China

Study of CM310 in Patients With Allergic Rhinitis

Phase 2
Completed
Conditions
Allergic Rhinitis
Interventions
First Posted Date
2023-06-18
Last Posted Date
2024-11-08
Lead Sponsor
Keymed Biosciences Co.Ltd
Target Recruit Count
100
Registration Number
NCT05908721
Locations
🇨🇳

Beijing Tong-Ren hospital, Beijing, China

A Study of CM310 in Subjects With Moderate to Severe Asthma

Phase 2
Recruiting
Conditions
Moderate to Severe Asthma
Interventions
Other: Placebo
First Posted Date
2023-03-09
Last Posted Date
2023-12-15
Lead Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Target Recruit Count
600
Registration Number
NCT05761028
Locations
🇨🇳

China-Japan Friendship Hospital, Beijing, Beijin, China

Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2023-02-08
Last Posted Date
2024-10-15
Lead Sponsor
Keymed Biosciences Co.Ltd
Target Recruit Count
160
Registration Number
NCT05715320
Locations
🇨🇳

Hangzhou First People's Hospital, Hangzhou, Zhejiang, China

Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2023-01-27
Last Posted Date
2024-10-15
Lead Sponsor
Keymed Biosciences Co.Ltd
Target Recruit Count
240
Registration Number
NCT05702450
Locations
🇨🇳

PKUCare Luzhong Hospital, Zibo, China

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2022-10-14
Last Posted Date
2024-11-08
Lead Sponsor
Keymed Biosciences Co.Ltd
Target Recruit Count
24
Registration Number
NCT05579925
Locations
🇨🇳

Beijing Children's Hospital Capital Medical University, Beijing, China

A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）

Phase 3
Completed
Conditions
Chronic Rhinosinusitis With Nasal Polyposis
Interventions
Biological: Placebo
First Posted Date
2022-06-29
Last Posted Date
2024-11-08
Lead Sponsor
Keymed Biosciences Co.Ltd
Target Recruit Count
180
Registration Number
NCT05436275
Locations
🇨🇳

Beijing Tongren Hospital, CMU, Beijing, Beijing, China

A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis

Phase 3
Completed
Conditions
Atopic Dermatitis
Interventions
Other: Placebo
First Posted Date
2022-03-04
Last Posted Date
2024-11-08
Lead Sponsor
Keymed Biosciences Co.Ltd
Target Recruit Count
500
Registration Number
NCT05265923
Locations
🇨🇳

Peking University People's hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy